aEvents occurring in ≥ 10% of Neulasta®-treated patients and at a higher incidence as compared to placebo-treated patients. bBone pain is limited to the specified adverse event term, "bone pain."
Based on a composite analysis using multiple, related adverse event terms to describe
bone pain resulted in incidence of mild-to-moderate bone pain of 57% vs 50% in
Neulasta®-treated patients and in placebo-treated patients respectively.
Neulasta® (pegfilgrastim) is indicated to decrease the incidence
of infection, as manifested by febrile neutropenia, in patients with nonmyeloid
malignancies receiving myelosuppressive anticancer drugs associated with a clinically
significant incidence of febrile neutropenia.
